Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001350001 | SCV001544371 | uncertain significance | Familial acute necrotizing encephalopathy | 2020-09-26 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine with glutamine at codon 2622 of the RANBP2 protein (p.Lys2622Gln). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and glutamine. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with RANBP2-related conditions. This variant is present in population databases (rs749548826, ExAC 0.009%). |
Ambry Genetics | RCV004036602 | SCV004934425 | uncertain significance | not specified | 2022-09-07 | criteria provided, single submitter | clinical testing | The c.7864A>C (p.K2622Q) alteration is located in exon 21 (coding exon 21) of the RANBP2 gene. This alteration results from a A to C substitution at nucleotide position 7864, causing the lysine (K) at amino acid position 2622 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |